{"disease":{"id":"acute-bacterial-bronchitis","name":"Acute bacterial bronchitis","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":19,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"azithromycin","indication_name":"Acute bacterial bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zithromax","generic_name":"azithromycin","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Canalicular multispecific organic anion transporter 1, Taste receptor type 2 member 4, Motilin receptor","drug_class":"Macrolide antibiotic (azalide)","quality_score":67,"revenue":"399","mechanism":"Macrolide antibiotic that binds the 50S ribosomal subunit, inhibiting bacterial protein synthesis with an exceptionally long tissue half-life."},{"drug_id":"gemifloxacin-mesylate","indication_name":"Acute bacterial bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Factive","generic_name":"GEMIFLOXACIN MESYLATE","company_name":"Lg Chem Ltd","drug_phase":"marketed","molecular_target":"","drug_class":"Quinolone Antimicrobial","quality_score":49,"revenue":null,"mechanism":""},{"drug_id":"gemifloxacin","indication_name":"Acute bacterial bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Factive","generic_name":"GEMIFLOXACIN","company_name":"Lg Chem Ltd","drug_phase":"marketed","molecular_target":"","drug_class":"Quinolone Antimicrobial","quality_score":49,"revenue":null,"mechanism":""},{"drug_id":"cefaclor","indication_name":"Acute bacterial bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ceclor","generic_name":"CEFACLOR","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"cefaclor","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"ciprofloxacine","indication_name":"Acute bacterial bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ciprofloxacine","company_name":"Poitiers University Hospital","drug_phase":"discontinued","molecular_target":"DNA topoisomerase II, DNA gyrase subunit A, DNA gyrase subunit A","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Acute Bacterial Exacerbation of Chronic Bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"alatrofloxacin","indication_name":"Acute bacterial bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"ALATROFLOXACIN","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"alatrofloxacin","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"cefprozil","indication_name":"Acute bacterial bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cefzil","generic_name":"cefprozil","company_name":"Teva Pharmaceuticals USA","drug_phase":"marketed","molecular_target":"","drug_class":"Cephalosporin Antibacterial [EPC]","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"atm-avi","indication_name":"Treatment of acute bacterial exacerbation of chronic bronchitis (ABECB) caused by Haemophilus influenzae, Haemophilus parainfluenzae, or Moraxella catarrhalis.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Atm-Avi","generic_name":"atm-avi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"unknown","drug_class":"antibiotic","quality_score":37,"revenue":null,"mechanism":"ATM-AVI's mechanism of action is not specified on Wikipedia."},{"drug_id":"atm-avi","indication_name":"Treatment of acute bacterial exacerbation of chronic bronchitis (ABECB) caused by Haemophilus influenzae, Haemophilus parainfluenzae, or Moraxella catarrhalis in patients who have a penicillin tolerance test result of >= 20 mcg/mL.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Atm-Avi","generic_name":"atm-avi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"unknown","drug_class":"antibiotic","quality_score":37,"revenue":null,"mechanism":"ATM-AVI's mechanism of action is not specified on Wikipedia."},{"drug_id":"grepafloxacin","indication_name":"Acute bacterial bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tomefloxacin","generic_name":"GREPAFLOXACIN","company_name":"Otsuka","drug_phase":"marketed","molecular_target":"Potassium voltage-gated channel subfamily H member 2","drug_class":"grepafloxacin","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"ceftibuten","indication_name":"Acute bacterial bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cedax","generic_name":"ceftibuten","company_name":"Burke Therap","drug_phase":"marketed","molecular_target":"","drug_class":"Cephalosporin Antibacterial","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"cefpodoxime-proxetil","indication_name":"Acute bacterial bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vantin","generic_name":"CEFPODOXIME PROXETIL","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Cephalosporin Antibacterial","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Acute bacterial exacerbation of chronic bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"sparfloxacin","indication_name":"Acute bacterial bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sparcin","generic_name":"SPARFLOXACIN","company_name":"","drug_phase":"marketed","molecular_target":"Potassium voltage-gated channel subfamily H member 2","drug_class":"High Risk QT Prolonging Agents","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"norfloxacin","indication_name":"Acute bacterial bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Noroxin","generic_name":"NORFLOXACIN","company_name":"","drug_phase":"marketed","molecular_target":"Gamma-aminobutyric acid receptor subunit alpha-1","drug_class":"Quinolone Antimicrobial","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"ofloxacin","indication_name":"Acute bacterial bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Floxin","generic_name":"OFLOXACIN","company_name":"","drug_phase":"marketed","molecular_target":"Histamine H3 receptor","drug_class":"Quinolone Antimicrobial [EPC]","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"dirithromycin","indication_name":"Acute bacterial bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dirythromycin","generic_name":"DIRITHROMYCIN","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"dirithromycin","quality_score":32,"revenue":null,"mechanism":""},{"drug_id":"ciprofloxacin","indication_name":"Acute bacterial bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cipro","generic_name":"ciprofloxacin","company_name":"Bayer AG","drug_phase":"marketed","molecular_target":"DNA topoisomerase II, DNA gyrase subunit A, DNA gyrase subunit A","drug_class":"Fluoroquinolone antibiotic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"clarithromycin","indication_name":"Acute bacterial bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Biaxin","generic_name":"clarithromycin","company_name":"Generic (originally Abbott/AbbVie)","drug_phase":"marketed","molecular_target":"Potassium voltage-gated channel subfamily H member 2","drug_class":"Macrolide Antimicrobial [EPC]","quality_score":65,"revenue":null,"mechanism":"Clarithromycin is a macrolide antimicrobial drug."},{"drug_id":"cefixime","indication_name":"Acute bacterial bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Suprax","generic_name":"CEFIXIME","company_name":"","drug_phase":"marketed","molecular_target":"1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1","drug_class":"cefixime","quality_score":10,"revenue":null,"mechanism":"Suprax works by inhibiting the bacterial enzyme 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1, disrupting bacterial cell wall synthesis."},{"drug_id":"levofloxacin","indication_name":"Acute bacterial bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Levaquin","generic_name":"levofloxacin","company_name":"Generic (originally Daiichi Sankyo/J&J)","drug_phase":"marketed","molecular_target":"CAAX prenyl protease 2, Multidrug and toxin extrusion protein 1, Potassium voltage-gated channel subfamily H member 2","drug_class":"Fluoroquinolone Antibacterial [EPC]","quality_score":65,"revenue":null,"mechanism":"Levofloxacin is a fluoroquinolone antibacterial agent."},{"drug_id":"cefpodoxime","indication_name":"Acute bacterial exacerbation of chronic bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cefpodoxime Proxetil","generic_name":"CEFPODOXIME","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"ofloxacine","indication_name":"Acute bacterial bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ofloxacine","company_name":"Assistance Publique - Hôpitaux de Paris","drug_phase":"phase_3","molecular_target":"Gamma-aminobutyric acid receptor subunit alpha-2, Histamine H3 receptor, Muscarinic acetylcholine receptor M1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":24,"totalPipeline":0},"trials":{"data":[],"total":0},"guidelines":[],"source":"Drug Landscape verified database"}